Arthneeti
NGL Fine Chem Ltd Q2 FY27 results are out (Jul–Sep 2026) →Revenue ₹159 CrSee revenue, profit and what management said. You are viewing Q3 FY24.
NF

NGL Fine Chem Ltd

Q3 FY24Pharmaceuticals & Biotechnology

NGL Fine Chem Q3 FY24: Revenue ₹87.95 Cr, PAT ₹10.03 Cr

Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹88Cr
Net profit
₹10Cr
Margin
16%

Based on NGL Fine Chem Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,895
Market cap₹1.7K Cr
P/E33.9

The short version

Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). EBITDA (Q3FY24): ₹13.87 crores - Year-on-Year (YoY) growth: +41.32% - EBITDA Margin (Q3FY24): 15.77% (up 213 bps YoY) - Operating Margin: - Total Operating Expenses for Q3FY24: ₹74.08 crores - Profit After Tax (PAT) (Q3FY24): ₹10.03 crores - YoY growth: +54.68% - Margin Outlook: - Management commentary notes marginal contract in margins this quarter due to slight raw material cost increase but expresses confidence in gradual sequential margin improvement going forward.

From NGL Fine Chem Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8).
  • Volume growth mentioned as a key driver of topline increase, despite competitive pricing pressures (Page 6).
  • Revenue from Veterinary API segment for FY23 was ₹258 crore, showing a 15% CAGR over FY19-FY23 (Page 11).
  • Outlook: Positive demand signals and recovery across markets, particularly exports (Bangladesh, Egypt), give confidence in gradual margin improvement and volume growth.

2 more points from NGL Fine Chem Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Greenfield expansion at Tarapur through subsidiary Macrotech:
  • Completed expansion with additional intermediates capacity; commercial production started.
  • 50% capacity expansion planned to meet demand for new products.
  • Estimated total capex: ₹140 crore, funded through debt and internal accruals.
  • Civil construction ongoing; ₹45 crore invested till Q3FY24.
  • CAPEX project with phases:
  • Phase 1: Investment of ₹75 crore planned, ₹45 crore already invested.
  • Includes establishing utilities and operationalizing one clean room (API line).
  • Target completion by end of Q2FY25.
  • Phase 2: Involves activating remaining 5 clean rooms.
  • Planned operationalization by December 2025.
  • Additional ₹25 crore expected from internal accruals for both phases.

2 more points from NGL Fine Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pharmaceuticals
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what NGL Fine Chem Ltd said on order book & pipeline — free account, 30 seconds.

NGL Fine Chem Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

NGL Fine Chem Ltd Q3 FY24 results — key figures

NGL Fine Chem Ltd Q3 FY24 reported results vs year-ago quarter, ₹ crore
₹ CrQ3 FY24Q2 FY24QoQ
Revenue8880+10%
Operating profit (EBITDA)14140%
Operating margin16%17%-1 pp
Profit before tax14140%
Net profit (PAT)10100%
EPS (₹)16.2416.96-4.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What NGL Fine Chem's management said in earlier quarters

Earlier calls (8)

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt (Q3 FY24)

    Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key concall takeaways from Wockhardt Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.

  • Anuh Pharma (Q3 FY24)

    172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key concall takeaways from Anuh Pharma Ltd's Q3 FY24 earnings call — and how it…

  • Bharat Parenterals (Q3 FY24)

    Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key concall takeaways from Bharat Parenterals Ltd's Q3 FY24 earnings call — and how it ranks against…

  • Themis Medicare (Q3 FY24)

    82.51 Cr, down 7.06% year-on-year from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were NGL Fine Chem Ltd Q3 FY24 results?

Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). EBITDA (Q3FY24): ₹13.87 crores - Year-on-Year (YoY) growth: +41.32% - EBITDA Margin (Q3FY24): 15.77% (up 213 bps YoY) - Operating Margin: - Total Operating Expenses for Q3FY24: ₹74.08 crores - Profit After Tax (PAT) (Q3FY24): ₹10.03 crores - YoY growth: +54.68% - Margin Outlook: - Management commentary notes marginal contract in margins this quarter due to slight raw material cost increase but expresses confidence in gradual sequential margin improvement going forward.

What is NGL Fine Chem Ltd share price analysis?

NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem Ltd planning capital expenditure?

Greenfield expansion at Tarapur through subsidiary Macrotech: - Completed expansion with additional intermediates capacity; commercial production started.

Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.